Read this manager's filing book
Disclosed positions
ARCH Venture Management, LLC: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- PARABILIS MEDICINES INC
- Ticker
- PBLS
- Class
- COM
- Reported value
- $175,517,789
- Reported amount
- 6,412,780
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001012975-26-000794Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| PARABILIS MEDICINES INC | PBLS | COM | $175,517,789 | 6,412,780 | SH | None |
| BEAM THERAPEUTICS INC | BEAM | COM | $155,771,929 | 4,540,132 | SH | None |
| RAPPORT THERAPEUTICS INC | RAPP | COM | $155,376,512 | 3,728,738 | SH | None |
| SEAPORT THERAPEUTICS INC | SPTX | COMMON STOCK | $136,600,437 | 6,294,951 | SH | None |
| ERASCA INC | ERAS | COM | $129,917,324 | 7,091,557 | SH | None |
| VIR BIOTECHNOLOGY INC | VIR | COM | $129,353,521 | 12,694,163 | SH | None |
| MAZE THERAPEUTICS INC | MAZE | COM | $122,983,582 | 4,120,053 | SH | None |
| LYELL IMMUNOPHARMA INC | LYEL | COM NEW | $45,525,211 | 3,247,162 | SH | None |
| GENERATE BIOMEDICINES INC | GENB | COM SHS | $32,802,467 | 1,944,426 | SH | None |
| 10X GENOMICS INC | TXG | CL A COM | $8,351,756 | 217,834 | SH | None |
| BOUNDLESS BIO INC | BOLD | COM | $6,735,238 | 2,694,095 | SH | None |
| GOSSAMER BIO INC | GOSS | COM | $1,326,004 | 8,055,916 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.